AstraZeneca Aims To Grow Seroquel XR With Added Indications, Not Switches
Executive Summary
AstraZeneca is looking to establish Seroquel XR, the sustained-release line extension of its atypical antipsychotic quetiapine, by adding unique indications rather than pushing to switch patients from immediate-release Seroquel
You may also be interested in...
Is FDA Less Confident In ANDAs? Stay On Efudex Generic May Set Precedent
FDA's decision to review its approval of a generic for Valeant's topical Efudex (fluorouracil) Cream 5% may create a precedent for future approvals of ANDAs for complex small molecule drugs and could set the stage for higher hurdles for eventual approvals of biogenerics
Is FDA Less Confident In ANDAs? Stay On Efudex Generic May Set Precedent
FDA's decision to review its approval of a generic for Valeant's topical Efudex (fluorouracil) Cream 5% may create a precedent for future approvals of ANDAs for complex small molecule drugs and could set the stage for higher hurdles for eventual approvals of biogenerics
AstraZeneca Sales Force Restructuring Boosts Operating Profit, Not Sales
AstraZeneca's efforts to restructure its EU sales force have helped the company improve its margins